Two separate lawsuits filed against the makers of popular GLP-1 drugs are moving through the court system, and both raise questions about what patients were told before they started treatment. One case targets Eli Lilly over Mounjaro or Zepbound. The other targets Novo Nordisk, with claims that the company withheld information about serious risks. For anyone currently using or considering these medications, these cases are worth watching as they unfold.
The lawsuit against Eli Lilly, known as Borstler v. Eli Lilly & Company, involves a patient who took either Mounjaro or Zepbound and has since taken legal action against the drugmaker. The case remains active in court, which means no ruling or settlement has been reached yet. Because the case is still working its way through the legal process, the specific claims and any eventual outcome are not yet public in full detail. Patients who use either drug may want to follow how this case develops, since court filings often reveal new information as they proceed.
The second lawsuit, Stewart v. Novo Nordisk A/S, centers on a claim that the company knew about serious risks tied to its GLP-1 drugs and did not disclose them to patients before she experienced harm. This kind of claim, if proven, would suggest a gap between what the company knew internally and what patients were told at the point of prescription. The case is still in its early stages, so the allegations have not yet been tested in court. Anyone taking a Novo Nordisk GLP-1 medication may find it useful to stay informed as more details come out through the legal process.
Neither case has reached a resolution, so there is no verdict or settlement to report yet. If you currently take Mounjaro, Zepbound, or a GLP-1 drug made by Novo Nordisk, it may help to keep an eye on how these lawsuits progress and to raise any concerns about side effects with your doctor. Court records tend to update over time, and new filings can add context that is not available today.
Key details
A patient's active lawsuit against Eli Lilly over Mounjaro or Zepbound is still working…
A patient alleges Novo Nordisk hid serious risks tied to its GLP-1 drugs before she…
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-07-29